Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA ...

Psoriasis is a notoriously competitive market, where Novartis’ Cosentyx (secukinumab) is fast gaining momentum, but the expectation is that Skyrizi will become a blockbuster several times over ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

However, the analyst wrote in a client note Tuesday, icotrokinra seems less effective than Skyrizi and Tremfya ... or IGA, and the Psoriasis Area and Severity Index, or PASI.

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

ORKA-001 distinguishes itself from existing treatments such as SKYRIZI through its innovative ... candidate in the competitive landscape of psoriasis treatments, supporting the Buy rating and ...